Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features

Although previous studies demonstrated benefit in the addition of cytoreductive therapy in patients with essential thrombocythemia (ET) who are at high risk for thrombosis, a recent study of 382 patients with ET showed no significant difference between hydroxycarbamide plus aspirin versus aspirin alone in those at low risk for thrombosis.

Journal of Clinical Oncology